glp-1 obesity drug updates today Weight loss with medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine The GLP-1 Access Gap: Mapping

Results Despite heterogeneity in study designs and populations, a largely consistent association was found between GLP-1RA use and a reduced incidence of glaucoma

In the stomach, GLP-1s slow down gastric emptying, that is, they keep food in the stomach longer than normally occurs, thus giving you a sense of fullness (satiety) you may not have experienced before

doi: 10.3390/ijms24021703

Demand for GLP-1 therapies has increased sharply, driven largely by obesity treatment

Liraglutide is a GLP-1 receptor agonist that helps manage type 2 diabetes mellitus (T2DM) by stimulating insulin secretion and suppressing glucagon

GLP-1 effects on food intake and body weight One of the most frequently described extrapancreatic effects of pharmacokinetically-optimized GLP-1R analogs is their ability to lower body weight via centrally regulated inhibition of food intake (Figure 7)